Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by MeadowBrook Investment Advisors LLC

MeadowBrook Investment Advisors LLC lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 40.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,305 shares of the medical equipment provider’s stock after acquiring an additional 660 shares during the period. MeadowBrook Investment Advisors LLC’s holdings in Lantheus were worth $206,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. GAMMA Investing LLC lifted its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 146 shares during the period. CWM LLC grew its stake in shares of Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 290 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Lantheus by 57.1% during the 3rd quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 460 shares in the last quarter. Finally, Procyon Advisors LLC grew its stake in Lantheus by 16.0% during the 3rd quarter. Procyon Advisors LLC now owns 3,252 shares of the medical equipment provider’s stock valued at $357,000 after purchasing an additional 449 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is owned by company insiders.

Lantheus Price Performance

Shares of Lantheus stock opened at $81.92 on Wednesday. The business’s fifty day moving average price is $91.89 and its two-hundred day moving average price is $98.24. The company has a market capitalization of $5.70 billion, a P/E ratio of 13.63 and a beta of 0.44. Lantheus Holdings, Inc. has a 1-year low of $54.69 and a 1-year high of $126.89.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on LNTH shares. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.